The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
15 total results
Showing 1 featured result
Showing results 1 - 10 of 14
The Biomedical Prevention Implementation Collaborative (BioPIC)
The pipeline for HIV prevention products holds the potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort. The Biomedical Prevention Implementation Collaborative is pioneering an innovative, integrated and adaptable approach to product introduction, with a focus on injectable cabotegravir (CAB) for…
BioPIC Adaptable Product Introduction Framework
This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in…
Community/Advocacy, Demand Creation/Marketing, Financing & Costing, Research, Monitoring & Evaluation, Service Delivery, Supply Chain Management
Shaping and Coordinating the Implementation Science Agenda for Injectable Cabotegravir for PrEP: The role of the Biomedical Prevention Implementation Collaborative (BioPIC)
This article from JIAS describes the coordinated approach taken by the Biomedical Prevention Implementation Collaborative (BioPIC) to ensure questions regarding delivery of cabotegravir (CAB) for PrEP are addressed so that CAB can be introduced in low- and middle-income countries in timely, acceptable and effective ways.
BioPIC CAB for PrEP Study Compendium
This compendium provides detail on planned and ongoing studies related to landscaping, product introduction, introduction studies, and implementation research for Cabotegravir for PrEP and is a companion to the Implementation Study Tracker. If you would like to add your study to the compendium, please contact Catherine Verde Hashim.
Integrated Study Dashboard
This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using…
Generating Demand for HIV Biomedical Prevention in the Era of Choice
In light of the emerging need to (re-)define how to generate demand for choice in HIV biomedical prevention, AVAC, under BioPIC, convened program implementers; social and behavioural change communication, marketing, and design thinking experts; behavioral economists; researchers; donors; and civil society to identify proven and promising strategies and models to more effectively reach and engage…
Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models
This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.
Coordinating Implementation Science for CAB for PrEP: Focus on Research and Surveillance during Pregnancy and Breastfeeding
These notes outline the key takeaways of a Think Tank focussing on CAB for PrEP implementation research and surveillance during pregnancy and breastfeeding. The Think Tank was part of an ongoing series by BioPIC and the WHO on coordinating implementation science for injectable CAB for PrEP.
Monitoring & Evaluation, Research
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Slides
These slides were featured at the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and…
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Report
This report was from the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP…
Modelling Impact of Injectable Cabotegravir for PrEP on Drug Resistance
An important consideration in the scale-up of injectable cabotegravir (CAB) for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on…
Financing & Costing, Testing